Supernus Pharmaceuticals（SUPN）的股东，即将迎来一项重大资产转换。根据最新披露的信息，他们手中持有的每一股Supernus Pharmaceuticals股份，将对应换取1.5401股Indivior Pharmaceuticals（INDV）的普通股。这一兑换比例，清晰地勾勒出两家公司间交易结构的核心轮廓。
Supernus Pharmaceuticals（SUPN）的股东，即将迎来一项重大资产转换。根据最新披露的信息，他们手中持有的每一股Supernus Pharmaceuticals股份，将对应换取1.5401股Indivior Pharmaceuticals（INDV）的普通股。这一兑换比例，清晰地勾勒出两家公司间交易结构的核心轮廓。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.